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Introduction. Postural instability is a known contributing factor to balance dysfunction and increased fall risk in those with
Parkinson’s disease (PD). Computerized posturography employing a force platform system provides objective, quantitative as-
sessments of postural control impairments. 'is study examines balance performance as measured by force platform (FP) tests in
persons with PD compared to age-matched healthy adults. Secondarily, we examine if these FP measures provide diagnostic and
clinically meaningful information about the underlying balance impairments in the PD population. Methods. Participants—42
individuals with PD (Hoehn and Yahr stage � 2.33 ± 0.77) and 55 age-matched healthy adults—were assessed on three standardized
balance measures on a computerized force platform system. Between groups, comparisons of FP performance were analyzed using
independent t-test. Within the group, comparisons for the PD cohort were analyzed using ANOVA for comparing disease stage and
Mann–WhitneyU test for PD subtypes. Results. 'e PD cohort demonstrated significantly greater postural instability on the sensory
organization test (SOT)measures (P � 0.013, CI-95% � 1.286 to 10.37) and slower movement velocity on the limits of stability (LOS)
test (P � 0.001, CI-95% � 0.597 to 1.595) than the healthy cohort, suggesting that these tests were sensitive to detect sensory
integration and voluntary postural control deficits in the PD cohort. Within the PD group, the SOT differentiated between H&Y
stages 1–3.'emotor control test (MCT) detected changes in reactive postural control mainly in later disease stages. All three FP tests
distinguished between PD subtypes, with the Posture Gait Instability subtype demonstrating poorer balance performance than
Tremor Dominant subtype. Conclusion. 'ese findings suggest FP measures provide clinically meaningful, diagnostic information in
the examination of balance impairments in individuals with PD. FP measures may inform clinicians regarding intrinsic balance
deficits and guide them in designing targeted balance interventions to reduce fall risk in persons with PD.
1. Introduction
Parkinson’s disease (PD) is a chronic progressive neuro-
logical disorder that involves both motor and nonmotor
symptoms [1, 2]. 'e most common motor symptoms of PD
include bradykinesia, rigidity, tremor, and postural in-
stability, which result in functional decline and disability [2].
PD is a highly prevalent disorder, as it is estimated that
819,000 individuals will be diagnosed by 2020 and 1.06
million by 2030 [3]. In 2010, it was estimated that those
living with PD incurred over 14 billion dollars in medical
expenses [3]. It is well established that those with PD are at a
high fall risk [4–10]. Research suggests that 35–70% of those
with PD experience multiple falls and are at a nine times
higher risk for falls than age-matched healthy individuals
[4, 5]. Falls can not only lead to serious injury but may also
have a negative impact on mobility, activities of daily living,
emotional well-being, and quality of life [6]. 'erefore, it is
important to identify sensitive clinical measures that detect
balance impairments to better direct individualized fall
prevention programs.
Falls in PD are largely multifactorial and intrinsic in
nature [4–6]. Deficits in postural control mechanisms are a
key contributor to instability. 'ose with PD have increased
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postural sway during both static and dynamic activities,
resulting in reduced limits of stability and functional balance
[10, 11]. Anticipatory postural strategies are often di-
minished, possibly due to impairments with feed-forward
mechanisms for movement and balance [12]. Individuals
with PD also have reduced reactive postural responses,
which can result in insufficient balance strategies in response
to perturbations and increased fall risk [13]. Additionally,
those with PD tend to select inappropriate postural strategies
and have abnormal sequencing of muscle activation, leading
to inefficient postural strategies [14]. Impaired central
processing of proprioceptive and vestibular information also
contributes to postural instability, resulting in increased
reliance on vision to maintain balance [15, 16].
When examining patients with PD, it is important to
assess the mechanisms of postural instability and underlying
balance impairments to identify fall risk and guide physical
therapy interventions. 'e Parkinson Evidence Database to
Guide Effectiveness and the Movement Disorder Society
(MDS) developed recommendations for balance examina-
tion in the PD population [17, 18]. However, the recom-
mended balance measures are limited as the majority of
these clinical tests evaluate balance at the activity or func-
tional task level without examining the underlying postural
control impairments at the body structure and function level
[19–21]. King et al. [21] found that functional measures used
to assess balance at the activity level were not responsive for
detecting changes after balance interventions in persons
with PD. In addition, these tests rely primarily on subjective
scoring scales [22]. 'e MDS (2016) suggests that more
research is needed on balance and posture control measures
with regard to the diagnosis of balance impairments, sen-
sitivity to measure change, and applicability across the
disease spectrum [17]. Force platform systems provide ob-
jective and quantitative assessments for diagnosis of postural
control impairments in persons with PD.
'e NeuroCom force platform system is a computerized
system used to examine underlying balance deficits in pa-
tients with neurologic conditions and in the elderly at fall
risk. Standardized force platform (FP) measures on this
system include limits of stability (LOS) test, sensory orga-
nization test (SOT), and motor control test (MCT), which
assess voluntary postural control, sensory integration, and
reactive postural control, respectively. 'ese FP measures
provide quantitative data on postural sway, movement
amplitude and velocity, sensory strategies, and latency of
postural responses. 'ese measures have been applied in
elderly to identify balance impairments and fall risk. 'e
SOT and LOS test validly identify postural control im-
pairments in the elderly fallers, differentiate fallers from
nonfallers, and predict fall risk [23–26]. 'ese FP measures
are also supported as reliable and valid measures of un-
derlying postural control deficits across neurological pop-
ulations [27–30]. Specific to the PD population, Harro et al.
[31] reported excellent test-retest reliability for these FP
measures, and fair to moderate correlation between the SOT
and LOS test and clinical balance measures.
Regarding the PD population, limited research supports
that FP measures may identify balance impairments, even in
early disease stages, and may detect balance decline with
disease progression [32–35]. Rossi-Izquierdo et al. [36]
found that the SOT and LOS test differentiated between PD
and healthy groups and between fallers from nonfallers
within the PD cohort. Colnat-Coulbois et al. [37] reported
that the SOTdetected postural control deficits in persons in
late stage PD. 'e LOS test identified impaired voluntary
postural control in both medial-lateral and posterior di-
rections in persons in the early stages of PD [38, 39]. Re-
duced movement velocity on the LOS test has been
correlated with reduced gait speed and stride length in
persons with PD [40]. Frenklach et al. [41] found that
postural sway in both static and dynamic conditions on FP
significantly increases with PD progression. 'ere is limited
evidence specifically regarding the MCT in the PD pop-
ulation, but several foundational studies utilized FP trans-
lations to assess reactive postural control strategies and
found that persons with PD demonstrated impaired reactive
strategies [42–44]. Particularly, in response to posterior
perturbations, individuals with PD had smaller stability
margins, increased motor response latency, and took more
steps than healthy controls [42–44]. 'is preliminary evi-
dence suggests that FP measures may provide important
diagnostic information regarding balance function and
decline with disease progression in PD, but further research
is needed.'ere is also limited research supporting the use of
FP measures to measure changes in postural control fol-
lowing exercise-based interventions in PD [45, 46].
Further research on the clinical utility of the FPmeasures
in the PD population is warranted due to the current gaps in
the literature. Although there are valid and reliable clinical
measures of balance at the functional level, there is a lack of
rigorous research on balance measures at the impairment
level. Further research is needed on computerized FP
measures to assess if these measures identify balance deficits
in PD across the disease stages and are able to sensitively
assess changes in balance function with disease progression.
In addition, further research is needed to examine if these
measures are able to distinguish between balance impair-
ments in persons with PD and age-related changes in bal-
ance in healthy older adults.
'e purpose of this study is to compare balance per-
formance on the LOS test, SOT, and MCT in persons with
PD with age- and gender-matched healthy adults. Second-
arily, this study will assist clinicians in determining if these
standardized FP measures provide diagnostic and clinically
meaningful information about the underlying balance im-
pairments in the PD population. 'is research may help
clinicians select examination measures to identify balance
deficits across disease stages in persons with PD, which may
direct balance interventions to reduce fall risk.
2. Methods
2.1. Research Design. 'is study examines the differences in
postural control between individuals with PD and an age-
and gender-matched healthy cohort, as measured by stan-
dardized tests on the NeuroCom force platform system. 'e
study analyzes between-group comparisons on the LOS test,
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MCT, and SOT, and examines if there were differences in
test performance within the PD cohort based on disease
stage, PD subtype, and age grouping.
2.2. Participants. 'is study’s recruitment and participant
enrollment took place from June 2014 to March 2016.
Recruitment methods included posting information in
local Parkinson association newsletters, posting flyers in
the community and local university, and conducting in-
formational meetings at local PD support groups and
community exercise classes. Recruitment of age- and
gender-matched healthy adult controls was based on the
following age groupings: 41–50, 51–60, 61–70, and 71–80
years old. Inclusion and exclusion criteria used for both
cohorts are listed in Table 1.
Researchers conducted phone interviews to determine if
participants met the inclusion and exclusion criteria, fol-
lowed by an in-person visit to assess walking and stair ability
and to administer the Montreal Cognitive Assessment
(MoCA) and the Semmes Weinstein monofilament
(SWME). A MoCA cutoff score of 21/30 points for identi-
fying dementia was used for both groups (sensitivity 81%,
specificity 95% in PD) [47]. SWME scores of five or more
insensate points (out of 8 testing points) were considered
indicative of sensory neuropathy (sensitivity of 0.77, spec-
ificity of 0.96) [48]. 'ose individuals who met the inclusion
criteria were enrolled in the study and completed the in-
formed consent process. 'e Grand Valley State University
Institutional Review Board approved this study.
Medical history, activity self-report, and history of
falls within the last six months were collected from all
participants and/or their spouses. Falls were defined as
any instance in which the individual lost their balance,
causing them to fall to the ground or hit an object below
them. Participants were classified as “fallers” if they re-
ported 2 or more falls in the last 6 months. Information
regarding disease characteristics and severity for the PD
cohort was gathered through the freezing of gait ques-
tionnaire (FOGQ) and the Movement Disorder Society-
sponsored revision of the unified Parkinson’s disease
rating scale (MDS-UPDRS), which was administered by
the principal investigator who had completed training and
certification by the MDS. Participants were classified as
“freezers” if they scored greater than one on the third item
of the FOGQ. PD participants were classified into three
PD subtypes based on their MDS-UPDRS score as de-
scribed by Stebbins et al.: (1) tremor predominant (TD),
(2) postural instability and gait difficulty (PIGD), and (3)
indeterminate (I) [49].
As depicted in Figure 1, 68 individuals for the PD cohort
and 67 individuals for the healthy cohort were recruited,
with 42 and 55 qualified participants in the respective co-
horts. Table 2 provides summary of group demographics.
'e mean Hoehn and Yahr (H&Y) stage in the PD cohort
was 2.33 (±0.77), and the mean disease duration was 53.90
(±37.86) months. In the PD cohort, 24% were “fallers,” and
24% were classified as “freezers.” 'ere were no “fallers” in
the healthy cohort.
2.3. Testing Procedures. 'is study was part of a larger study
examining the reliability and concurrent validity of FP
measures in individuals with PD, with detailed description
of the full study’s methods published by Harro et al. [31].
Data were collected in the university’s biomechanics labo-
ratory, a quiet, controlled environment. Participants com-
pleted a 1.5-hour testing session as outlined in Figure 2, with
rest periods provided between testing segments. Tests were
conducted in a standardized order for both cohorts. A
second test session was completed within 10 days of the first
session with readministration of the FP tests and rapid step
test (RST) in order to examine test-retest reliability of these
measures. 'is reliability data is published in a separate
paper [31].'e PD cohort was tested during the “on time” of
their medication and at a similar time of day for both test
sessions. Each group of tests was carried out by the same
researcher to maintain consistency and standardize the
testing procedures.
2.4. Force Platform Measures. 'e NeuroCom™ Smart
Equitest Clinical Research System/Balance Master System
9.1 was used to administer the LOS test, MCT, and SOT
(Natus Medical Inc., 9570 SE Lawnfield Rd, Clackamas, OR,
97015). Participants were barefoot for the FP testing. Foot
placement on the platform was carefully controlled, and
standardized instructions were given for each test. Per
testing protocol guidelines, participants wore an overhead
harness and were closely guarded during testing. A “fall”
during any of the tests was defined as needing to take a step,
using hands on the walls, or requiring assistance from the
researcher to regain balance. Reliability and validity of these
measures in persons with PD was discussed earlier in this
paper [27–29, 31].
2.4.1. Limits of Stability (LOS). 'is test assesses voluntary
postural control as demonstrated by participants moving
their center of gravity towards eight targets when cued by a
visual signal on-screen. 'e test variables recorded for this
study were endpoint excursion (EPE), average movement
velocity (Avg MV), endpoint excursion to posterior targets
4, 5, and 6 (EPE 4–6), total number of falls, and number of
falls during posterior targets 4, 5, and 6.
2.4.2. Motor Control Test (MCT). 'is test assesses reactive
postural control in response to anterior and posterior
perturbations induced by movements of the force platform
surface. 'e test variables recorded for this study were the
average response latency (Avg Lat), average amplitude of
response to large perturbations (Avg Amp L), average
posterior amplitude (Avg Posterior Amp), and average
posterior latency (Avg Posterior Lat) in response to posterior
perturbations.
2.4.3. Sensory Organization Test (SOT). 'is test measures
postural sway in response to six different sensory conditions
that challenge the integration of vision, somatosensory, and
vestibular senses. 'e test variables recorded in this study
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were composite equilibrium score (Comp Eq), vestibular
ratio (Vestib Ratio), visual preference ratio, total number of
falls, and number of falls in conditions 5 and 6.
2.5. Data Analysis. Data collected were used to examine if
there were dierences in performance on the FP tests be-
tween the PD cohort and the age-matched healthy cohort.
Table 1: Inclusion and exclusion criteria for Parkinson’s disease cohort and age-matched healthy cohort.
Participant cohort Inclusion criteria Exclusion criteria
Parkinson’s
disease cohort
(1) Idiopathic PD
(2) Dementia based on scores from the Montreal Cognitive
Assessment (MoCA)
(3) Self-reported vestibular pathology
(4) Peripheral neuropathy as assessed by the Semmes Weinstein
monolament test (SWME)
(5) Deep brain stimulation
(6) Acute orthopedic injury or surgery that limits the ability to walk
or ascend and descend stairs within the past three months
(7) Inability to speak/understand English
(1) Other neurological diagnosis
(2) Hoehn and Yahr stage I–IV
(3) Between 20 and 80 years of age
(4) Functional vision with or without
corrective lenses
(5) Ability to walk 300 feet with or without
an assistive device with no more than close
guard assist
(6) Ability to ascend and descend 6 stairs
with or without a railing or assistive device
with no more than close guard assist
(7) Stable PD medication for the last three
months per patient report
Healthy
age-matched
cohort
(1) Between 20 and 80 years of age
(2) Functional vision with or without corrective lenses
(3) Able to ascend and descend 6 steps without help from another
person, with or without railing
(4) Able to walk 300 feet without assistance
Excluded (2):
(i) Dropped out due to change in
medical status (n = 1)
(ii) Did not return to second session or
complete part of testing protocol
(n = 1)
n = 42
n = 55
n = 55
n = 44
n = 57n = 54
n = 67n = 68
Parkinson’s cohort
Excluded (0)
Dropped out:
Family reasons (n = 2)(i)
Travel (n = 1)(ii)
Excluded (10):
Reasons for exclusion:
Peripheral neuropathy (n = 4)(i)
Dementia (n = 3)(ii)
Excluded (2):
Undiagnosed or previously
diagnosed vestibular
pathology (n = 2)
(i)
Excluded (10):
Reasons for exclusion:
(i) Age > 80 (n = 1)
Orthopedic condition
(n = 1)
(ii)
Vestibular dxn (n = 5)(iii)
Schedule conflict (n = 1)(iv)
TIA (n = 2)(v)
Excluded (14):
Reasons for exclusion:
Past neurological dxn (n = 2)(i)
(ii) Vestibular dxn (n = 1)
(iii) Orthopedic limitation (n = 1)
(iv) Age > 80 (n = 5)
(v) Poor vision (n = 2)
(vi) New PD medicaton (n = 1)
(vii) Not idiopathic PD (n = 1)
(viii) DBS (n = 1)
(ix) Dementia per spouse (n = 1)
(x) Schedule conflict (n = 1)
Phone screen
In-person screen
Testing session
Testing session
Healthy cohort
Figure 1: Participant ow diagram.
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Using multiple linear regression, it was determined that 46
participants were needed in the PD cohort to maintain a
statistical power of 0.80 and achieve an effect size of 0.35 and
an alpha level of 0.05 [50]. 'erefore, we were slightly
underpowered (N � 42). Descriptive statistics were analyzed
to determine the mean and standard deviation for the
primary FP variables (SOT Comp Eq, LOS Avg EPE, and
MCTAvg Lat) and secondary FP variables including (1) LOS
test measures (Avg MV, EPE 4–6, total number of falls, and
number of posterior falls 4–6), (2) MCTmeasures (Avg Amp
L, Avg Posterior Amp, and Avg Posterior Lat), and (3) SOT
measures (total number of falls, number of falls in conditions
5 and 6, Vestib Ratio, and visual preference).
Discriminative validity was analyzed between the PD
and healthy cohorts by using unpooled independent t-tests
for all FP variables, alpha level set at P< 0.05. ANCOVA
analysis was utilized to examine whether performance on the
primary FP measures varied between the cohorts when
controlling for age as a covariate. Estimated variance was
reported for variables in which significant between-group
differences were found [51].
'e secondary research purpose was addressed using
subgroup analysis within the PD cohort to examine if FP
performance differed based on disease severity, age grouping,
and PD subtype (TD and PIGD). Comparison of H&Y stage
4 was excluded as there was only one participant in this group.
One-way ANOVA was utilized to assess if there were dif-
ferences in mean performance on the LOS Avg EPE and
Avg MV and MCT Avg Lat among the disease stages. Post
hoc analysis was completed with adjusted Bonferroni
corrections for multiple comparisons. Kruskal–Wallis
analysis was used to assess if there were differences in
median performance on the SOT Comp Eq among disease
stages, as equality of variance could not be assumed. Post
hoc analysis was completed using a Wilcoxon rank-sum
test with adjusted Bonferroni correction for multiple
comparisons (P< 0.017).
Subgroup analyses were performed for the PD cohort
based on the PD subtype (PIGD and TD). Subgroup analyses
for the primary FP variables (SOT Comp Eq, LOS Avg EPE,
and MCT Avg Lat) are reported by Harro et al. in a previous
paper [31]. 'e Mann–Whitney U test was analyzed to
determine if there were differences between PD subtypes,
TD and PIGD, for the secondary FP variables.
A one-way ANOVA was used to assess if there were
differences in mean performance on primary FP variables
based on the age group within the PD cohort. Age groups
were established as group 1 (41–60 years), group 2 (61–70
years), and group 3 (71–80 years) [52]. Post hoc analysis was
completed with adjusted Bonferroni corrections for multiple
comparisons.
3. Results
3.1. Between-Group Comparisons on FP Measures.
Descriptive statistics for FP balance measures for both the
PD and healthy cohorts are summarized in Table 3. Sig-
nificant differences between the PD and healthy cohorts in
mean performance were found for the following SOT var-
iables: composite equilibrium (P � 0.013, CI-95% � 1.286 to
10.37), vestibular ratio (P � 0.027, CI-95% � 0.12 to 0.185),
and number of total falls (P � 0.015, CI-95% � −1.527 to−0.175) (Table 4). Individuals with PD demonstrated sig-
nificantly lower SOTcomposite equilibrium scores (PD:M �
68.52 (SD 12.93) vs. healthy: M � 74.35 (SD 8.05), Figure 3)
and vestibular ratio scores (PD: M � 0.54 (SD 0.24) vs.
healthy:M � 0.64 (SD 0.16)).'e PD cohort had significantly
more falls on the SOT (PD: M � 1.21 (SD 2.07) vs. healthy:
M � 0.36 (SD 0.80)). No significant differences were found
between the cohorts in performance on the LOS test or
MCT, with the exception of LOS average movement velocity
(P � 0.001, CI-95% � 0.597 to 1.595, Figure 4).'e PD had a
lower mean average movement velocity than the healthy
cohort (PD:M � 3.35 (SD 1.02)m/s vs. healthy:M � 4.45 (SD
1.45)m/s). 'ere was high variability in the PD cohort for
both the SOT Comp Eq and LOS Ave MV measures (Fig-
ures 3 and 4).
ANCOVA analysis examined whether FP performance
varied between the PD and healthy cohorts when controlling
for age. 'e overall models for all three primary variables
were significant (SOT Comp Eq F(2,94) � 7.95, P � 0.001;
LOS Avg EPE F(2,94) � 16.41, P< 0.0001; MCT Avg Lat F
(2,94) � 4.28 (2), P � 0.017)). However, SOT Comp Eq was
the only variable in which significant between-group dif-
ferences were found when controlling for age (F(2,9) � 6.4,
P � 0.013). Based on estimates from this analysis, a par-
ticipant in the healthy cohort had, on average, a SOT Comp
Eq score of 5.28 points higher than a participant of the same
age in the PD cohort.
3.2. Comparison of PD Stage, Subtype, and Age Group.
Within the PD cohort, significant differences were found in
MCT Avg Lat among H&Y stages (F(2,38) � 4.20, P � 0.023).
Table 2: Demographics for Parkinson’s disease cohort and age-
matched healthy cohort.
PD cohort Healthy cohort
Number of participants N � 42 N � 55
Age 66.21 ± 7.92 64.75 ± 8.50
Gender
Male N � 22 N � 24
Female N � 20 N � 31
Disease duration (months) 53.90 ± 37.86 N/AHoehn and Yahr stage 2.33 ± 0.77
Stage 1 N � 7
N/AStage 2 N � 15Stage 3 N � 19
Stage 4 N � 1
MDS-UPDRS total score 47.98 ± 23.70 N/A
MDS-UPDRS motor score 25.95 ± 14.51 N/A
Number of medications 4.30 ± 3.01 2.31 ± 1.69
Percentage of fallers 24% 0%
Percentage of freezers 24% N/A
PD subtype
(1) Tremor dominant N � 17 N/A
(2) Posture instability
and gait difficulty N � 17 N/A
(3) Indeterminate N � 8 N/A
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Clinical gait measures Clinical balance measures Force platform measures
(1) 10 meter walk test
(2) 6 minute walk test
(3) Rapid step test
(4) MiniBEST
(5) Functional gait
assessment
(6) Limits of stability test
(7) Motor control test
(8) Sensory organization test
Figure 2: Testing protocol utilized for both Parkinson’s disease and healthy cohorts.
Table 3: Descriptive statistics of force platform measures.
Cohort FP measures Mean SD Minimum Q1 Median Q3 Maximum
Parkinson’s
disease
cohort
(N  42)
SOT composite equilibrium (1–100) 68.52 12.93 24.00 64.00 72.50 77.00 83.00
SOT vestibular ratio (0-1) 0.54 0.24 0.00 0.47 0.61 0.72 0.85
SOT visual preference 0.98 0.13 0.69 0.91 0.98 1.04 1.32
SOT fall number 1.21 2.07 0.00 0.00 0.00 1.00 8.00
SOT fall number-conditions 5 and 6 1.12 1.82 0.00 0.00 0.00 1.00 6.00
LOS average endpoint excursion (%) 70.58 13.71 36.63 61.25 74.50 80.00 104.60
LOS movement velocity (m/s) 3.35 1.02 1.35 2.64 3.31 4.01 7.35
LOS number of falls 0.43 0.77 0.00 0.00 0.00 1.00 3.00
LOS number of falls on targets 4, 5, and 6 0.33 0.61 0.00 0.00 0.00 1.00 2.00
LOS average endpoint excursion on targets 4, 5, and 6 (%) 61.99 16.45 26.33 49.67 61.84 72.00 103.33
MCT average latency (ms) 144.12 9.21 118.00 139.00 145.50 150.00 161.00
MCT average amplitude to large perturbations
(degrees/second) 10.23 3.52 3.00 7.75 9.63 12.50 19.75
MCT average posterior amplitude (degrees/second) 7.68 2.72 2.17 5.33 7.17 10.00 13.67
MCT average posterior latency (ms) 151.98 10.84 125.00 145.00 151.67 161.67 170.00
Healthy
cohort
(N  55)
SOT composite equilibrium (1–100) 74.35 8.05 48.00 70.00 75.00 80.00 86.00
SOT vestibular ratio (0-1) 0.64 0.16 0.00 0.57 0.67 0.75 0.92
SOT visual preference 0.99 0.11 0.72 0.93 1.00 1.05 1.42
SOT fall number 0.36 0.80 0.00 0.00 0.00 0.00 4.00
SOT fall number-conditions 5 and 6 0.35 0.80 0.00 0.00 0.00 0.00 4.00
LOS average endpoint excursion (%) 72.97 14.19 36.00 64.13 75.88 83.50 97.75
LOS movement velocity (m/s) 4.45 1.45 2.29 3.26 4.18 5.79 8.06
LOS number of falls 0.40 0.89 0.00 0.00 0.00 0.00 4.00
LOS number of falls on targets 4, 5, and 6 0.16 0.57 0.00 0.00 0.00 0.00 3.00
LOS average endpoint excursion on targets 4, 5, and 6 (%) 62.42 16.57 14.67 50.00 62.33 74.67 97.67
MCT average latency (ms) 142.62 8.77 126.00 136.00 141.00 148.00 165.00
MCT average amplitude to large perturbations
(degrees/second) 10.19 2.82 5.50 7.75 10.00 11.75 16.50
MCT average posterior amplitude (degrees/second) 7.18 2.22 3.50 5.50 7.00 8.17 12.50
MCT average posterior latency (ms) 149.91 11.15 131.67 141.67 146.67 158.33 185.00
SOT, sensory organization test; LOS, limits of stability test; MCT, motor control test; SD, standard deviation; Q1, lower quartile; Q3, upper quartile.
Table 4: Discriminative validity of force platform measures between PD and healthy cohorts.
Force platform variable T statistic (df) P value 95% condence interval
SOT composite equilibrium (1–100) 2.56 (64.563) 0.013∗ 1.286, 10.357
SOT vestibular ratio (0-1) 2.26 (68.555) 0.027∗ 0.012, 0.185
SOT visual preference 0.37 (80.477) 0.710 −0.039, 0.057
SOT fall number −2.53 (50.466) 0.015∗ −1.527, −0.175
LOS average endpoint excursion (%) 0.81 (89.681) 0.422 −3.367, 7.964
LOS movement velocity (m/s) 4.36 (94.456) <0.001∗ 0.597, 1.595
LOS number of falls −0.17 (93.594) 0.866 −0.365, 0.308
LOS number of falls on targets 4, 5, and 6 −1.39 (85.006) 0.167 −0.412, 0.072
LOS average endpoint excursion on targets 4, 5, and 6 (%) 0.13 (88.294) 0.899 −6.288, 7.512
MCT average latency (ms) −0.81 (86.129) 0.419 −5.175, 2.174
MCT average amplitude to large perturbations (degrees/second) −0.06 (76.892) 0.949 −1.364, 1.279
Independent t-tests between Parkinson’s and healthy cohort are represented. ∗¤e signicance level set at alpha <0.05. SOT, sensory organization test; LOS,
limits of stability test; MCT, motor control test; df, degrees of freedom.
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Post hoc analysis demonstrated signicant dierences between
H&Y stages 1 and 3 (P  0.028), as individuals in stage 3 had
slower postural latencies than those in stage 1 (M  147.74 (SD
7.30)m/s; vs. M  137.29 (SD 7.23); respectively). ¤ere were
also signicant dierences in median SOT Comp Eq among
H&Y stages (x2(2)  10.949, P  0.004). Post hoc analysis
revealed that there was a signicant dierence in the median
SOT Comp Eq score between those in H&Y stages 2 and 3
(P  0.001) and those in stages 1 and 3 (P  0.017)( Figure 5).
Individuals in stage 3 (Mdn  61.79) had lower postural sta-
bility scores on SOT than those in stages 1 or 2 (Mdn  74.00;
Mdn  75.47; respectively). No signicant dierences were
found among disease stages for the LOS test variables, Avg EPE
(F  (2,38) 2.68, P  0.082) or Avg MV (F(2,38)  0.41,
P  0.665).
Previous analysis of the primary FP measures in this
study, Harro et al. [31], revealed signicant dierences
between PD subtypes in SOT Comp Eq, LOS EPE, and MCT
Ave Lat, with the PIGD group performing poorer on all
primary FP balance measures than the TD group. Further
analysis of secondary FP measures revealed signicant
dierences between PD subtypes, TD and PIGD, for median
performance in LOS EPE 4, 5, and 6 (Z  1.89, P  0.029)
andMCTAvg Post Lat (Z  −2.19, P  0.009) (Figure 6).¤e
voluntary LOS excursion to posterior targets was less in the
PIGD group (Mdn  55.00%) compared to the TD group
(Mdn  71.00%), and median reactive latency to posterior
perturbations was longer in the PIGD group (Mdn  160ms)
than the TD group (Mdn  155ms). Additionally, the dif-
ference in the median number of falls for the SOT was
approaching signicance (Z  −1.617, P  0.055), with the
PIGD group experiencing a higher number of median falls
than the TD group (Mdn  1, Mdn  0, respectively).
Signicant dierences were found between age groups
within the PD cohort in LOS Avg EPE (F(2,39)  8.84,
P  0.01), specically between the 71- to 80-year-old group
and the 41- to 60-year-old group (M  57.88 (SD 13.56) and
M  79.73 (SD 13.56), respectively, P  0.001) and between
the 71–80-year-old group and the 61–70-year-old group (M
 57.88 (SD 13.55) and M  72.81 (SD 10.12), P  0.005).
Limits of stability excursion was signicantly reduced in the
71 to 80-year-old age group as compared to the 41–60 and
61–70-year-old age groups. No signicant dierences were
found among age groups for MCT Avg Lat (F(2,39)  3.05,
P  0.059) and SOT Comp Eq (F(2,39)  1.97, P  0.153).
4. Discussion
4.1. Comparison of Force Platform Measures in PD and
Healthy Individuals. ¤is study compared FP measures of
balance impairment in persons with PD and an age-matched
healthy cohort and demonstrated that sensory organization
test (SOT) measures and limits of stability (LOS) movement
velocity were signicantly dierent between the two groups.
¤e PD cohort had slower movement velocity during vol-
untary postural control in the LOS test as compared to
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Figure 3: Comparative boxplot of sensory organization test
composite equilibrium score for Parkinson’s disease and age-
matched healthy cohorts.
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Figure 4: Comparative boxplot of limits of stability average
movement velocity performance for Parkinson’s disease and age-
matched healthy cohorts. LOS, limits of stability.
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Figure 5: Comparative boxplot of sensory organization test
composite equilibrium performance of Parkinson’s disease cohort
based on the Hoehn and Yahr stage. Hoehn and Yahr stage 4 was
not included in this analysis as only one participant was repre-
sented in this stage. SOT, sensory organization test.
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healthy controls. Individuals with PD had reduced postural
stability on the SOT (Comp Eq score), lower equilibrium
scores in conditions requiring eective use of vestibular cues
(Vestib ratio), and an increased number of falls during the
SOT when compared to healthy controls, reective of sen-
sory integration decits aecting balance control. ¤e SOT
dierentiated between PD and healthy controls, as the Comp
Eq score was estimated to be 5.88 higher in healthy in-
dividuals than those with PD when controlling for age.
Our ndings regarding identication of postural in-
stability based on SOT results in persons with PD compared
to healthy individuals are consistent with previous research
[7, 37, 41]. Colnat-Coulbois et al. [37] and Rossi et al. [7] also
reported that persons with PD had a lower SOT vestibular
ratio, reecting impaired use of vestibular information for
balance under varied environmental conditions. Even in
early-to-middle disease stages, our ndings suggest that
persons with PD have postural instability when in chal-
lenging or conicting sensory conditions necessitating the
use of the vestibular system. Early identication of sensory
processing and integration decits related to balance
function can inform clinicians regarding the need for tar-
geted balance interventions to train the vestibular system to
more eectively process and weigh sensory cues, thereby
potentially reducing an individual’s fall risk.
Individuals with PD displayed reduced movement ve-
locity on the LOS test, which may reect underlying bra-
dykinesia aecting voluntarymovements and impaired feed-
forward balance strategies and is consistent with two other
studies [7, 40]. Slower, less eªcient control of center of mass
movements may adversely aect balance during self-
generated movements for daily functional tasks, such as
picking shoes up o the oor or reaching into a high cabinet.
Given that individuals with PD tend to have anteriorly
biased postural alignment and often demonstrate diªculty
shifting their weight backwards, researchers expected that
the LOS endpoint excursion to posterior targets would be
signicantly reduced compared to healthy controls. Sur-
prisingly, this nding was not supported in our results.
However, researchers directly observed that participants
with PD used ineªcient strategies and were less successful in
reaching posterior targets compared to forward and lateral
targets during the LOS testing. ¤e majority of both our PD
and healthy cohorts were elderly (>60 years old). It is
possible that healthy elderly also have an anterior bias in
COM, which may have contributed to the lack of signicant
dierences in LOS to posterior targets between the two
groups. Previous research reported reduced composite
endpoint excursion (EPE) on the LOS test in persons with
PD, but this was not supported in our ndings [7, 39, 53].
¤ese dierences in research ndings may be explained by
the previous studies’ use of dierent computerized pos-
turography systems and their inclusion of individuals with
more advanced stages of PD than our PD cohort.
Currently, there is limited published research onMCT FP
performance, a measure of reactive postural control, in
persons with early-to-middle stage PD. Dimitrova et al. and
Horak et al. [42, 43] examined electromyography during
automatic postural responses and reported that individuals
with PD had slowed motor latency, inappropriate muscle
coactivation, and disordered muscular responses to external
perturbations. Our ndings from the MCT measures, how-
ever, did not show impaired reactive postural control in
persons with early-to-middle stage PD. In agreement with our
results, Lee et al. did not nd any signicant dierences
between healthy and PD cohorts on theMCT [44]. In Horak’s
study, there was a larger representation of later disease se-
verity (H&Y stages 3 and 4) as compared to our study and
Lee’s study, which lends support that reactive balance
strategies may decline more notably in later stages of PD.
Additionally, through partial correlation analysis of this
study’s data, Harro et al. [31] found that the strongest disease
characteristic associated with MCT average latency measure
was disease severity, as measured by the UPDRS total score.
¤is nding may further support that MCT is clinically in-
dicated to detect impaired postural responses to perturbations
in those in H&Y stages 3 and 4 but not in early stages.
4.2. Force Platform Performance of PD Cohort by Disease
Severity, PD Subtype, and Age. When examining perfor-
mance dierences within the PD cohort among H&Y stages,
the SOTdistinguished between those individuals in stages 1
and 3 and those in stages 2 and 3. Additionally, the SOT
showed a moderate relationship to disease severity (MDS-
UPDRS) [31]. ¤ese ndings suggest that the SOTmay be a
good measure to detect decline in sensory processing and
integration across disease stages. ¤e SOT provides quan-
titative data not available from most clinical balance mea-
sures and, based on our ndings, has particularly good
diagnostic value for persons in H&Y stage 3. Likewise, the
MCT may sensitively identify a decline in balance with
advancing disease, as MCT latency was signicantly slower
for those in stage 3 as compared to stage 1. ¤ese dierences
in SOTand MCTmeasures across stages must be interpreted
cautiously however, since sample sizes for H&Y stages in this
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Figure 6: Comparative boxplot of motor control test posterior
latency performance of Parkinson’s disease cohort based on the PD
subtype. Subtype 3 was not included in this analysis as it is an
intermediate group with symptoms specic to both subtypes 1 and
2. MCT, motor control test. 1: tremor dominant. 2: postural in-
stability and gait dysfunction.
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study were small (stage 1 � 7, stage 2 � 15, and stage 3 � 19).
Further research should examine this comparison of FP
measures across stages with larger subgroup sizes. Both
measures may be a valuable addition to the evaluation of
postural control in middle stages of PD to assess underlying
balance impairments and diagnose if there is a decline in
balance function. 'ese measures may also be useful for
assessing the effectiveness of directed balance interventions.
Our research findings support that individuals with the
posture instability gait Difficulty (PIGD) subtype of PD have
greater underlying balance impairments than those with the
tremor dominant (TD) subtype. Based on analysis of this PD
cohort’s performance on primary FP measures, Harro et al.
[31] reported that participants in the PIGD subtype had
significantly lower SOT Comp Eq scores, lower LOS Avg
EPE scores, and slowed MCT average response latencies
compared to the TD subtype. Further analysis of secondary
FP measures also revealed that the PIGD group had de-
creased excursion to posterior targets in the LOS test and
slowed response latency to posterior perturbations on the
MCTcompared to the TD group. Regardless of disease stage,
subjects in the PIGD subtype demonstrated poorer balance
performance on FPM than the TD group, which lends
validity for these subgroup classifications. Clinicians may
therefore consider the need for more sensitive and di-
agnostic balance measures in the PIGD subgroup, such as
use of FP measures, to identify balance impairments and
potential fall risk. 'is study’s analysis of PD subtype was
based on 17 subjects in each of the PIGD and TD subgroups.
Further research is needed to expand on this analysis with
larger sample sizes.
Comparing FP balance performance between age groups
within the PD cohort, the LOS Avg EPE was the only
variable that demonstrated significant differences. Endpoint
excursion to targets was significantly reduced in the 71–80
year-old group when compared to both younger age groups.
Since LOS Avg EPE showed no differences between H&Y
stages, these results may indicate that age is a greater
contributing factor to reduced endpoint excursion than
disease stage. Older age (>70 years) combined with ad-
vancing PD stage may be a cause for concern of a decline in
feedforward, voluntary postural control needed for daily
functional tasks.
4.3. Clinical Implications. Force platform measures sensi-
tively detect balance impairments in persons with PD and
may be especially valuable for individuals with suspected
balance underlying impairments based on clinical functional
balance measures. 'e SOT provides clinically valuable
information regarding sensory organization strategies for
postural control and identifies a decline in these strategies
with increasing disease severity in PD. In contrast to the
modified clinical test of sensory interaction and balance
(Mod-CTSIB), which has fair reliability and validity at best
for measuring sensory organization deficits, the SOT has
excellent reliability (ICC � 0.90) and good validity [31] and
provides quantitative data regarding the use of visual, so-
matosensory, and vestibular systems for balance under
varied environmental conditions. By analyzing a patient’s
SOT findings, a clinician can create targeted interventions
that include multisensory balance training to promote op-
timal balance function in varied sensory environments.
Research supports that multisensory balance training is
effective in reducing fall risk and improving balance in
persons after stroke and elderly fallers [54, 55]. In in-
dividuals with early-to-middle stage PD, multisensory bal-
ance training paired with a highly challenging exercise
program was shown effective for improving balance and
reducing fall rate and fear of falling [56].
'e LOS test assesses voluntary postural control and
provides quantitative information about limits of stability
and speed of center of mass (COM) movement. 'is study’s
findings regarding reduced movement velocity on the LOS
test in the PD cohort may indicate a need for increased
attention in dynamic balance training to address full body
bradykinesia. Interventions to improve balance should
emphasize full body, self-generated, dynamic movements
targeting feed-forward anticipatory strategies for control of
balance. Based on our findings, the clinical use of the LOS
test may be especially beneficial for those with PD who are
categorized in the PIGD subtype and for those in middle to
later disease stages to detect balance deficits in feedforward
balance mechanisms [7, 40].
Results from this study indicated that there were not
deficits in reactive postural control strategies based on MCT
results in those in early stages (H&Y 1 and 2). Our findings
did support that the MCT appears to be an appropriate
diagnostic test to identify reactive balance control deficits for
patients in H&Y stages 3 and 4 and in those individuals with
PIGD subtype who are at greater risk for early balance
decline. If clinical balance assessments indicate suspected
deficits in reactive balance strategies, then the MCTmay be a
useful next step to provide objective, quantitative assessment
of this impairment and to assess the efficacy of reactive
balance training interventions.
4.4. Limitations and Future Research. Limitations in this
study related to sample characteristics include a lack of
representation of H&Y stage 4 (N � 1) and the exclusion of
individuals with dementia. 'erefore, our results regarding
the diagnostic value of FP measures cannot be generalized to
later disease stages or to those persons with significant
cognitive deficits. On average, the participants in our PD
cohort reported engaging regularly in physical activity.
'ese participants may have been more physically active
than the overall PD population, potentially limiting the
generalizability to more sedentary persons with PD. It is also
necessary to consider the potential for participation bias in
both the PD and healthy cohorts. Due to a sample of
convenience and the voluntary participation of subjects, it is
possible that individuals who were concerned about their
balance were more likely to participate in this study. 'e
samples sizes were relatively small for PD subgroup analysis
(by stage and PD subtype), yet despite this limitation, sig-
nificant differences in FP performance were found. Further
research is needed with a more robust subgroup sample size
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to further investigate if there are difference in FP measures
across disease severity or subtypes. Finally, as mentioned
above, this study was part of a larger study on reliability and
validity of FP measures in PD, which involved a 1.5-hour
testing protocol of balance and gait measures, with the FP
measures taken during the third segment of the testing
session. 'erefore, fatigue may have played a factor in FP
performance for both cohorts. Rest periods in sitting with
hydration were provided following each of the 3 testing
segments to minimize this factor. No participants in the PD
group requested or had to stop the testing session due to
fatigue.
Future research regarding the use of FP measures to
evaluate balance impairments and detect balance decline in
individuals with PD is warranted. 'is study was represen-
tative of individuals in H&Y stages 1–3; therefore, more
research is needed to assess the diagnostic value of these FP
measures in later disease stages when balance declines more
progressively, specifically stage 4. 'e PD cohort in our study
was not a representative sample of those with freezing of gait
characteristics and those with positive fall history (24% of our
sample had FOG; 24% of sample were fallers). Further re-
search examining the sensitivity of FP measures to identify
balance impairments and assess fall risk in individuals with
FOG deficits and positive fall history is warranted. It was not
the purpose of this study to examine if FP measures were a
valid assessment for fall risk and could predict future falls.
Research specifically targeting these important clinical
questions is needed. In addition, further research examining
the utilization of the FP measures to track changes in postural
control longitudinally in persons with PD is recommended to
shed light on the temporal course of postural control decline
in PD. Lastly, computerized posturography assesses postural
control mechanisms in the standing position on a force plate
system. Research is needed to evaluate the control of dynamic
balance during walking tasks in PD, such as varied speeds,
during turns, and walking over obstacles, using a motion
analysis system. 'is research would provide valuable insight
into postural control deficits that contribute to fall risk during
mobility and walking activities in those with PD.
5. Conclusions
'is study provides evidence for the discriminative validity of
force platform measures in assessing postural control im-
pairments in individuals with PD compared to a healthy, age-
matched cohort. 'e sensory organization test measures and
the limits of stability test movement velocity measure were
able to differentiate between the two cohorts, supporting the
premise that these measures detect PD-specific balance im-
pairments related to sensory integration and voluntary pos-
tural control, respectively. 'e PD cohort demonstrated
significantly greater postural instability on sensory organi-
zation test measures and slower movement velocity on the
limits of stability test than the healthy cohort. Additionally,
this study’s results support the diagnostic value of FP mea-
sures to examine underlying balance impairments related to
advancing disease severity, PD subtype (PIGD), and older age
in individuals with PD. 'e sensory organization test
differentiated between Hoehn and Yahr stages, sensitively
detecting postural instability and sensory integration deficits
with disease progression. 'e motor control test also dif-
ferentiated between disease stages and PD subtypes, with
poorer performance found in later disease stages and in those
with the postural instability and gait difficulty subtype. 'e
limits of stability test differentiated between PD subtypes and
age groups, with poorer balance performance found in those
greater than 70 years old and those with PIGD subtype.'ese
findings support that force platform measures may provide
clinically meaningful, quantitative information in the ex-
amination of balance impairments in individuals with PD.
Given the high fall rate and devastating sequelae of falls in
individuals with PD, force platform measures may inform
clinicians regarding an individual’s underlying balance defi-
cits and direct targeted balance interventions to remediate
postural control impairments and reduce fall risk.
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